The accessibility of immunotherapy is below 3% in India. Patients with head and neck cancers, those registered as private category and male patients had higher access to this therapy. There was also a temporal trend observed suggesting increased accessibility over the years.
No takes yet. Share an insight, caveat, or question.
Patil et al. (2022) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: